Sinexus Changes Name to Intersect ENT, Initiates Pivotal Study
PALO ALTO, Calif., Jan. 7 /PRNewswire/ -- Sinexus has changed its name to Intersect ENT. Intersect's initial focus is a bioabsorbable drug eluting stent to treat patients with chronic sinusitis, a debilitating condition that affects 37 million people each year and is more prevalent than heart disease or asthma.
The company also announced the initiation of its U.S. pivotal clinical study to evaluate the safety and effectiveness of its novel steroid-eluting bioabsorbable stent in patients undergoing sinus surgery. The prospective, randomized, blinded, multicenter study is guided by thought leaders in sinusitis care.
Dr. Marple added: "Patients with chronic sinusitis tend to require extensive oral steroids, which can lead to a multitude of side effects. Intersect's novel stents may alleviate the need for oral steroids and have the potential to become a powerful treatment option for sinus sufferers."
Intersect ENT Inc.